Life Technologies Corporation operates as a life sciences company.
The company's Research Consumables business group offers molecular and
cell biology reagents, endpoint PCR, and other benchtop instruments and
consumables, such as RNAi, DNA synthesis, sample prep, transfection,
cloning and protein expression profiling and protein analysis, cell
culture media used in research, stem cells and related tools, cellular
imaging products, antibodies, and cell therapy related products.
Its Genetic Analysis business group provides capillary
electrophoresis (CE) instruments used for research applications and
various CE consumables; real-time and digital qPCR instruments used in
research applications; qPCR consumables and genomic assays; and
sequencing systems and reagents for the SOLiD and Ion Torrent systems.
The company's Applied Sciences business group offers bioproduction,
forensics, and animal health and food safety reagent kits. Life
Technologies Corporation also provides repair and maintenance services;
and custom services, such as cell line development, custom media
modification, and primers and custom assays development services.
Its products offer research tools for genomics studies, proteomics
studies, gene splicing, cellular analysis, and other research
applications required by laboratories associated with universities,
medical research centers, and government and other research
institutions, as well as biotechnology, pharmaceutical, and chemical
companies.
To review Life's stock, please take a look at the 1-year chart of
LIFE (Life Technologies Company) below with my added notations:
After stalling near $50 for about (4) months, LIFE broke higher in
January. Since then, the stock has been hitting resistance at $65
(blue). A break through that resistance would be a new 52-week high for
the stock and should mean higher prices moving forward.
The Tale of the Tape: LIFE has a 52-week high
resistance at $65. A long trade could be entered on a break through that
level with a stop placed under it.
Please share this article
No comments:
Post a Comment